Mitsuhiro Abe

Mitsuhiro Abe

Auto-generated profile, based on publicly available information

Mitsuhiro Abe

Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
TNTsuneyuki Nagae
Tsuneyuki Nagae
KAKatsuo Aizawa
Katsuo Aizawa
NUNorio Uchimura
Norio Uchimura
DTDaisuke Tani
Daisuke Tani
MAMitsuhiro Abe
Mitsuhiro Abe
SIShin Ishimaru
Shin Ishimaru

1 July 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
MSMasashi Sakayori
Masashi Sakayori
JTJiro Terada
Jiro Terada
MAMitsuhiro Abe
Mitsuhiro Abe
YHYasutaka Hirasawa
Yasutaka Hirasawa
KSKenichi Suzuki
Kenichi Suzuki
KTKoichiro Tatsumi
Koichiro Tatsumi
Although pirfenidone (PFD) is a key drug for the treatment of idiopathic pulmonary fibrosis (IPF), differences in tolerability between elderly and young patients remain unclear. This study aimed to investigate age-related differences in adverse drug reactions to PFD and to evaluate whether patient age influences the safety and tolerability of PFD in clinical practice. One hundred fifty-four patients with IPF were treated with PFD in our institution between May 2009 and April 2017; these patients were classified into 2 groups on the basis of age: ≥75 years of age (elderly patients) and <75 years of age (younger patients). In each group, the clinical course, laboratory data, radiographic findings, adverse events, and tolerability of PFD at 6 months and 1 year after administration were retrospectively analyzed. Among the 120 patients examined in this study, 31 patients (26%) were ≥75 years of age. The continuation rate of PFD at 1 year in the elderly patient group was significantly lower (n=11 [35%] vs 57 [64%], p=0.007) than in the younger patient group. Regarding adverse drug reactions to PFD, the incidence of gastrointestinal disorders including anorexia (n=24 [77%] vs 40 [45%], p=0.002) and the discontinuation caused by gastrointestinal disorders (n=11 [35%] vs 13 [15%], p=0.019) were significantly higher in elderly patients than those in younger patients. However, with the exception of gastrointestinal disorders, other adverse drug reactions did not significantly differ between elderly and younger patients. Compared with younger patients, elderly patients with IPF had a higher incidence of gastrointestinal disorders, along with an increased discontinuation rate of PFD. More careful management of gastrointestinal disorders may be required to ensure continuation of PFD in elderly patients.

1 October 2018 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MAMitsuhiro Abe
Mitsuhiro Abe
KTKenji Tsushima
Kenji Tsushima
MSMasashi Sakayori
Masashi Sakayori
KSKenichi Suzuki
Kenichi Suzuki
JIJun Ikari
Jun Ikari
KTKoichiro Tatsumi
Koichiro Tatsumi
Introduction: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. Objectives: Reveal the utility and adverse events of nintedanib for severe IPF patients. Methods: This was a single-center retrospective study. Patients who met the eligibility criteria of the INPULSIS trial (%FVC ≥ 50%; %DLCO [diffusing capacity of the lung carbon monoxide % predicted] ≥ 30%) were classified as Mild to Moderate Group (n = 34); patients who did not meet the criteria were classified as Severe Group (n=17). Results: The body mass index (24.7 ± 3.4 vs 22.4 ± 3.6 kg/m2; P = 0.021) were significantly low in Severe Group. Main adverse events (diarrhea, nausea, liver disorder, and acute exacerbation) tended to be more in Severe Group than in Mild to Moderate Group; however, the difference was not significant (P = 0.76, 0.14, 0.18, and 0.67, respectively). The continuation rates over 12 months tended to be higher in Mild to Moderate Group than in Severe Group (77% vs 44%; P = 0.027). Log-rank test revealed that the prognosis was significantly better in Mild to Moderate Group than in Severe Group (P = 0.014). In the Severe Group, patients who were able to continue nintedanib for more than 3 months had significantly better prognosis compared to those who could not (P = 0.007). Conclusion: The benefit from nintedanib was reduced in patients in Severe Group when compared to those in Mild to Moderate Group; however, the prognosis is expected to improve with control of side effects and long-term administration. It is more important to control the side effects in Severe Group.

1 June 2020 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
YHYasutaka Hirasawa
Yasutaka Hirasawa
MAMitsuhiro Abe
Mitsuhiro Abe
JTJiro Terada
Jiro Terada
MSMasashi Sakayori
Masashi Sakayori
KSKenichi Suzuki
Kenichi Suzuki
KTKoichiro Tatsumi
Koichiro Tatsumi

Verified
Journal Article
Open access
PDF file
DIDaisuke Ishii
Daisuke Ishii
Takeshi KawasakiTakeshi Kawasaki
Takeshi Kawasaki
HSHironori Sato
Hironori Sato
KTKoichiro Tatsumi
Koichiro Tatsumi
TITakuro Imamoto
Takuro Imamoto
TSTakuji Suzuki
Takuji Suzuki
Two anti-fibrotic drugs, pirfenidone (PFD) and nintedanib (NTD), are currently used to treat idiopathic pulmonary fibrosis (IPF). Peripheral blood mononuclear cells (PBMCs) are immunocompetent cells that could orchestrate cell–cell interactions associated with IPF pathogenesis. We employed RNA sequencing to examine the transcriptome signature in the bulk PBMCs of patients with IPF and the effects of anti-fibrotic drugs on these signatures. Differentially expressed genes (DEGs) between “patients with IPF and healthy controls” and “before and after anti-fibrotic treatment” were analyzed. Enrichment analysis suggested that fatty acid elongation interferes with TGF-β/Smad signaling and the production of oxidative stress since treatment with NTD upregulates the fatty acid elongation enzymes ELOVL6. Treatment with PFD downregulates COL1A1, which produces wound-healing collagens because activated monocyte-derived macrophages participate in the production of collagen, type I, and alpha 1 during tissue damage. Plasminogen activator inhibitor-1 (PAI-1) regulates wound healing by inhibiting plasmin-mediated matrix metalloproteinase activation, and the inhibition of PAI-1 activity attenuates lung fibrosis. DEG analysis suggested that both the PFD and NTD upregulate SERPINE1, which regulates PAI-1 activity. This study embraces a novel approach by using RNA sequencing to examine PBMCs in IPF, potentially revealing systemic biomarkers or pathways that could be targeted for therapy.

10 November 2021 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
PDF file
KSKohei Shikano
Kohei Shikano
MAMitsuhiro Abe
Mitsuhiro Abe
YSYuki Shiko
Yuki Shiko
KTKenji Tsushima
Kenji Tsushima
KYKeiichiro Yoshioka
Keiichiro Yoshioka
KTKoichiro Tatsumi
Koichiro Tatsumi
Background: Bronchoalveolar lavage (BAL) is a useful examination for the evaluation of interstitial lung disease. A high BAL fluid (BALF) recovery rate is desirable because low recovery rates lead to inaccurate diagnoses and increased adverse events. Few studies have explored whether BALF recovery rates are influenced by clinical factors.Objectives: This study aimed to identify the clinical parameters affecting the recovery rates of BALF and the extent of their effects.Method: Data from patients who underwent BAL at the Chiba University Hospital between 2013 and 2019 were retrospectively reviewed. BAL was performed with three aliquots of 50‐ml physiological saline. The potential association of the BALF recovery rate with clinical parameters such as age, sex, smoking status, underlying disease, bronchus used for the procedure and pulmonary function, was analysed.Results: Eight hundred twenty‐six patients had undergone BAL. The average recovery rate was 52.4%. Factors affecting BALF recovery rates included male sex (odds ratio [OR]: 0.32, 95% confidence interval [CI]: 0.20–0.53, p < 0.001); age ≥ 65 years (OR: 0.50, 95% CI: 0.33–0.76, p < 0.001); use of the left bronchus (OR: 0.46, 95% CI: 0.30–0.71, p = 0.001) and bronchi other than the middle lobe bronchus or lingula (OR: 0.41, 95% CI: 0.25–0.65, p < 0.001); and forced expiratory volume in 1 s divided by forced vital capacity <80% (OR: 0.42, 95% CI: 0.40–1.00, p < 0.001).Conclusion: Sex, age, bronchus used for the procedure and pulmonary function may be useful as pre‐procedural predictors of BALF recovery rates.